Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed, page-26

Yep. And as for "a bit weak as substantiation for an additive effect", I respectfully suggest you stop with the Dunning Kruger-esque interpretations and read on past the pictures @vrs37:

Professor Kristofer Thurecht, University of Queensland, said, “The combination of Veyonda with LuPSMA
exhibited an impressive synergistic therapeutic response, with sustained and almost complete regression
of the tumour and minimally-observed systemic toxicity. This combined response was not observed in any
of the animals treated with monotherapy.”